We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.
Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.
Penny Stock of the Day: SCYNEXIS, Inc. (NASDAQ: SCYX)
Today’s penny stock pick is the biotechnology company, SCYNEXIS, Inc. (NASDAQ: SCYX).
SCYNEXIS, Inc. develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.
Website: https://www.scynexis.com
Latest 10-k report: https://ir.scynexis.com/sec-filings/all-sec-filings/content/0001564590-22-012199/scyx-10k_20211231.htm
Analyst Consensus: Guggenheim initiated coverage on SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and a price target of $8.
Potential Catalysts / Reasons for the Hype:
- CDC report about the spread of Candida auris, a drug-resistant fungus, in the US. Scynexis makes Ibrexafungerp, designed to fight fungal infections.
- Rumors of ibrexafungerp’s potential FDA approval, with market entry expected in late 2024/early 2025.
On analyzing the company’s stock charts, there seem to be multiple bullish indications…
Bullish Indications
#1 Falling Wedge Pattern Breakout: The daily chart shows that the stock has been forming a falling wedge pattern for the past several months. These are marked as purple color lines. It has typically taken support at the bottom of the wedge before bouncing back. The stock has currently broken out from the falling wedge pattern. Once the stock breaks out of the falling wedge pattern, it could move higher.
SCYX – Daily Chart
#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.
#3 Price above MA: The stock is currently above its 50-day SMA, indicating that the bulls have currently gained control.
#4 Bullish Stoch: The %K line of the stochastic is above the %D line, and has also moved higher from oversold levels, indicating possible bullishness.
#5 MACD above Signal Line: In the daily chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.
#6 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink color dotted line. This is a possible bullish indication.
SCYX – Weekly Chart
#7 Bullish Stoch: The %K line is above the %D line of the stochastic in the weekly chart as well, indicating possible bullishness.
Recommended Trade (based on the charts)
Buy Levels: If you want to get in on this trade, the ideal buy level for SCYX is above the price of $2.15.
Target Prices: Our first target is $3.00. If it closes above that level, the second target price is $3.60.
Stop Loss: To limit risk, place a stop loss at $1.70. Note that the stop loss is on a closing basis.
Our target potential upside is 40% to 67%.
For a risk of $0.45, our first target reward is $0.85, and the second target reward is $1.45. This is a nearly 1:2 and 1:3 risk-reward trade.
In other words, this trade offers 2x to 3x more potential upside than downside.
Potential Risks / Red Flags:
- The company has a history of net losses. SCYX reported a net loss of $32.9 million for the year ended December 31, 2021. As of December 31, 2021, the company had an accumulated deficit of approximately $359.5 million.
SCYX – Consolidated Statements of Operations
- The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
- Hedge Funds Decreased Holdings by 174.0K Shares Last Quarter.
Hedge Funds | Source: TipRanks.com
- Despite being a loss-making company, the executives are being paid significant compensation.
SCYX – Executive Compensation
- The company has never been profitable and has only one product approved for commercial sale, and to date, has generated limited revenue from product sales.
As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!
Happy Trading!
Trades of the Day Research Team
READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.
Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.
Dividend Expert Reveals His Biggest Income Secrets... Free of Charge [sponsor]Marc Lichtenfeld - Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package... Free of charge! Click Here to Get His #1 Dividend Stock... The Safest 8% Dividend in the World... Top Three "Extreme Dividend" Stocks, And Much, Much More.
Source: Trades of the Day